Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced its preliminary unaudited revenue for the first quarter of 2025, which is expected to be approximately $41.4 million. This figure includes about $6.2 million from sales of Motiva in the United States.
The company's interim CEO, Peter Caldini, has expressed optimism about the second quarter, stating that the United States launch of Motiva is accelerating. He highlighted that average orders in March surpassed 100 per day, and they expect this growth to continue, positioning their launch as one of the fastest in aesthetic history.
Establishment Labs also affirmed its previous guidance on revenue for 2025, expecting it to be in the range of $205 to $210 million. Additionally, the company anticipates turning EBITDA positive in 2025 and cash flow positive in 2026.
In terms of the impact of tariffs, the company indicated that they would represent less than a 50-basis point gross margin impact and would not change their trajectory.
Establishment Labs will be hosting an analyst and investor event in New York City on June 12, 2025, during which the leadership team and invited plastic surgeons will provide an update on the recent launch of Motiva in the United States, the company’s innovation roadmap, and the financial outlook.
The company's portfolio includes solutions for breast health, breast aesthetics, and breast reconstruction, which are available in over 90 countries. With over four million Motiva devices delivered to plastic and reconstructive surgeons since 2010, the company's products have set a new standard for safety and patient satisfaction.
Establishment Labs' minimally invasive platform consists of Mia FemTech®, Preservé™, and Gem®, among others, which are aimed at providing innovative solutions in breast aesthetics and reconstruction.
As a result of these announcements, the company's shares have moved -12.3% on the market, and are now trading at a price of $30.27. Check out the company's full 8-K submission here.
